$280 Million is the total value of Fairmount Funds Management LLC's 18 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 41.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| INSM | Sell | INSMED INC | $32,018,000 | -5.7% | 961,797 | -9.0% | 11.45% | -20.4% |
| FOLD | Sell | AMICUS THERAPEUTICS INC | $30,372,000 | +47.8% | 1,315,395 | -9.6% | 10.86% | +24.8% |
| IOVA | Sell | IOVANCE BIOTHERAPEUTICS INC | $26,257,000 | +33.6% | 565,890 | -5.2% | 9.39% | +12.8% |
| ACAD | Sell | ACADIA PHARMACEUTICALS INC | $24,074,000 | -9.9% | 450,317 | -30.5% | 8.61% | -23.9% |
| Sell | TRILLIUM THERAPEUTICS INC | $21,744,000 | -1.8% | 1,478,181 | -5.1% | 7.78% | -17.1% | |
| ALLK | Sell | ALLAKOS INC | $20,673,000 | +54.1% | 147,662 | -10.3% | 7.39% | +30.2% |
| ZGNX | Sell | ZOGENIX INC | $19,603,000 | +3.4% | 980,645 | -7.2% | 7.01% | -12.6% |
| AXSM | AXSOME THERAPEUTICS INC | $17,931,000 | +14.3% | 220,098 | 0.0% | 6.41% | -3.4% | |
| COGT | New | COGENT BIOSCIENCES INC | $17,507,000 | – | 1,558,975 | +100.0% | 6.26% | – |
| ARGX | ARGENX SEsponsored adr | $14,690,000 | +12.0% | 49,950 | 0.0% | 5.25% | -5.4% | |
| MRTX | Buy | MIRATI THERAPEUTICS INC | $13,288,000 | +128.6% | 60,500 | +72.9% | 4.75% | +93.1% |
| KPTI | KARYOPHARM THERAPEUTICS INC | $10,872,000 | +6.0% | 702,351 | 0.0% | 3.89% | -10.5% | |
| GBT | New | GLOBAL BLOOD THERAPEUTICS IN | $9,312,000 | – | 215,000 | +100.0% | 3.33% | – |
| AMRN | AMARIN CORP PLCspons adr new | $7,375,000 | +16.1% | 1,508,237 | 0.0% | 2.64% | -1.9% | |
| ENTA | Sell | ENANTA PHARMACEUTICALS INC | $6,333,000 | -14.7% | 150,433 | -7.3% | 2.26% | -28.0% |
| MCRB | New | SERES THERAPEUTICS INC | $6,297,000 | – | 257,016 | +100.0% | 2.25% | – |
| VRNA | VERONA PHARMA PLCsponsored ads | $700,000 | +12.2% | 100,000 | 0.0% | 0.25% | -5.3% | |
| MGEN | New | MIRAGEN THERAPEUTICS INC | $554,000 | – | 35,092 | +100.0% | 0.20% | – |
| KNSA | Exit | KINIKSA PHARMACEUTICALS LTD | $0 | – | -212,746 | -100.0% | -1.38% | – |
| NLTX | Exit | NEOLEUKIN THERAPEUTICS INC | $0 | – | -372,748 | -100.0% | -1.90% | – |
| UMRX | Exit | UNUM THERAPEUTICS INC | $0 | – | -6,235,903 | -100.0% | -5.81% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ARGENX SE | 16 | Q3 2023 | 9.3% |
| AXSOME THERAPEUTICS INC | 15 | Q3 2023 | 24.6% |
| INSMED INC | 12 | Q3 2022 | 15.0% |
| ACADIA PHARMACEUTICALS INC | 12 | Q3 2022 | 15.5% |
| IOVANCE BIOTHERAPEUTICS INC | 12 | Q3 2022 | 9.4% |
| COGENT BIOSCIENCES INC | 12 | Q3 2023 | 7.2% |
| ENANTA PHARMACEUTICALS INC | 12 | Q3 2022 | 9.6% |
| ALLAKOS INC | 12 | Q3 2022 | 7.4% |
| AMARIN CORP PLC | 12 | Q3 2022 | 10.9% |
| VERONA PHARMA PLC | 12 | Q2 2023 | 11.9% |
View Fairmount Funds Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | June 30, 2023 | 17,230,540 | 20.0% |
| Olema Pharmaceuticals, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| CATABASIS PHARMACEUTICALS INC | June 17, 2021 | 4,092,166 | 5.3% |
| MIRAGEN THERAPEUTICS, INC. | January 05, 2021 | 967,671 | 20.0% |
| Unum Therapeutics Inc. | July 10, 2020 | 7,482,460 | 20.0% |
View Fairmount Funds Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-25 |
| SC 13D/A | 2024-04-25 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
View Fairmount Funds Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.